Rimegepant: Effective Migraine Relief for Triptan-Unsuitable Adults

Research Summary

A recent study published in Cephalalgia explores the efficacy and tolerability of rimegepant, a calcitonin gene-related peptide antagonist, for adults with migraines who cannot use triptans. Conducted as a randomized, double-blind, placebo-controlled phase 4 trial, the research involved 585 participants who were unsuitable for triptans due to intolerance, lack of efficacy, or contraindications. Participants received a single 75-mg dose of rimegepant orally disintegrating tablet or placebo. Results showed that rimegepant significantly outperformed placebo in providing migraine pain relief at two hours, with 55.9% achieving relief compared to 32.7% with placebo. Rimegepant was well tolerated, with similar adverse event rates to placebo.

Study Details

📄 Title: Rimegepant for acute treatment of migraine in triptan-unsuitable adults: A randomized, double-blind, placebo-controlled phase 4 trial.

👥 Research Team: Ashina M et al.

📚 Published In: Cephalalgia

📅 Publication Date: 2025 Nov

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.